Onureg Tablet, Film Coated
Product Images NDC 59572-740

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Onureg (NDC 59572-740). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celgene Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Onureg 01)

Chemical structure of azacitidine, the active ingredient in ONUREG tablets. The structure shows a nucleoside analog consisting of a modified pyrimidine base attached to a ribose sugar.*

FDA Label Image

Figure 1 (Onureg 02)

Kaplan-Meier survival probability plot comparing ONUREG (azacitidine) with placebo over time in months from randomization. The graph shows survival probabilities on the y-axis and months on the x-axis, with ONUREG represented by a blue line and placebo by a red line. Censored data points are marked with circles. A table below the graph displays the number of subjects at risk over time for both ONUREG and placebo groups.*

FDA Label Image

Principal Display Panel (200 mg Bottle Label)

ONUREG 200 mg film-coated tablets label displaying the proprietary name, generic name azacitidine, dosage strength 200 mg, and oral tablet form. The label includes the NDC code 59572-730-14, manufacturer Celgene Corporation, and packaging details indicating 14 tablets per container. Additional instructions and cautions about tablet handling and storage are visible.*

FDA Label Image

Principal Display Panel (300 mg Bottle Label)

Packaging label for ONUREG (azacitidine) tablets 200 mg, oral film-coated tablets, from Celgene Corporation. The label includes a blister card design labeled for seven tablets with daily dosing slots for Days 1 through 7. It prominently displays a caution indication for hazardous agent handling. The NDC number 59572-730-07 is shown along with 'Rx only' and the Celgene logo.*

FDA Label Image

Onureg 05

Packaging label for ONUREG (azacitidine) 200 mg film-coated tablets by Celgene Corporation. The label indicates one blister card containing 7 tablets and includes the NDC 59572-730-07. It features operating instructions for opening the blister card and highlights the product as a prescription drug with caution for hazardous agent handling.*

FDA Label Image

Onureg 06

Packaging label for ONUREG (azacitidine) tablets, 200 mg film-coated oral tablets by Celgene Corporation. The label indicates one blister card containing 7 tablets. Storage instructions specify 20 to 25°C, with excursions permitted between 15 to 30°C. The label includes caution for hazardous agent handling and manufacturer details in Summit, NJ, USA, with product made in Switzerland.*

FDA Label Image

Onureg 07

ONUREG 300 mg film-coated oral tablets label shows the proprietary name, dosage strength (300 mg), dosage form, and that the package contains 14 tablets. It includes storage instructions, manufacturer Celgene Corporation, warnings such as 'Swallow whole' and 'CAUTION: Hazardous Agent.' The label also features the NDC 59572-740-14 and manufacturer location.*

FDA Label Image

Onureg 08

ONUREG 300 mg film-coated tablets blister card packaging label. Contains azacitidine as the active ingredient, with 7 tablets per blister. The label includes dosage instructions for daily intake over seven days and warns that the tablets are a hazardous agent. Manufactured by Celgene Corporation. The NDC is 59572-740-07.*

FDA Label Image

Onureg 09

Box packaging label for ONUREG (azacitidine) tablets, 300 mg, oral film-coated tablets. The label indicates one blister card containing 7 tablets and includes operating instructions for opening the blister pack. The product is labeled as prescription-only and manufactured by Celgene Corporation.*

FDA Label Image

Onureg 10

Packaging label for ONUREG (azacitidine) tablets, 300 mg, film-coated oral tablets. The label indicates each blister card contains 7 tablets. Manufactured by Celgene Corporation, Summit, NJ. Instructions note storage conditions and caution that the product is a hazardous agent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.